The discovery of human papillomavirus (HPV) DNA in cervical cancer by Harald zur Hausen
sparked 30 years of research that established that persistent cervical infection by certain …

Cervical cancer is the second leading cause of death from cancer in women worldwide.
Since the introduction of Papanicolaou smear-based screening in the 1950s, mortality from …

Human papillomavirus (HPV) causes cervical cancer in half a million women each year, and
two genotypes, 16 and 18, account for about 70% of all cervical cancers worldwide. 1 Two …

Screening can cause harm (eg, anxiety, further tests, diagnostic labels, costs, morbidity, and
death). Sometimes, a screening programme can bring net benefits when the Wilson and …

Cervical cancer is probably the best understood and most preventable of all major human
malignancies. The progressive steps of this disease—human papillomavirus (HPV) …

Vaccines have repeatedly proven successful in the fight against infectious diseases,
bringing some equity in health care to even the least developed regions of the world …

After prophylactic human papillomavirus (HPV) vaccina tion, cost-effectiveness models
predict that a reduction in cervical cancer will occur decades from now, but only when 90 …

In a pair of articles in The Lancet Oncology, Lehtinen and colleagues1 and Wheeler and
colleagues2 present 4-year end-of-study data from a trial of a prophylactic human …

Infection of the genital tract with human papillomaviruses (HPVs) is extremely common.
Among young sexually active women, about 50% are infected with HPV types that have the …

which showed 90% vaccine efficacy in the prevention of HPV 6, 11, 16, and 18 infections in
women naive to the relevant HPV type. To assess public health benefit, a different cohort …